Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Target Price at $1,008.96

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have been given an average rating of “Moderate Buy” by the twenty-two ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, sixteen have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $1,027.55.

Several equities research analysts have recently issued reports on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday, June 24th. Cantor Fitzgerald restated a “neutral” rating and issued a $925.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, May 3rd. Argus upped their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research report on Tuesday, June 25th. JPMorgan Chase & Co. lifted their target price on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now owns 1,382 shares in the company, valued at approximately $1,347,256.52. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total value of $1,142,535.92. Following the completion of the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at $1,347,256.52. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The disclosure for this sale can be found here. Insiders have sold 63,208 shares of company stock valued at $62,514,142 in the last three months. 7.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Sierra Summit Advisors LLC acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter worth about $1,011,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $749,000. Public Employees Retirement Association of Colorado raised its stake in shares of Regeneron Pharmaceuticals by 16.0% during the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock worth $14,118,000 after buying an additional 2,220 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after buying an additional 1,221 shares during the period. Finally, Congress Wealth Management LLC DE bought a new position in Regeneron Pharmaceuticals in the fourth quarter valued at approximately $271,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.0 %

Shares of NASDAQ:REGN opened at $1,024.09 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock’s 50-day moving average is $990.15 and its 200-day moving average is $954.11. The company has a market cap of $112.84 billion, a P/E ratio of 30.25, a P/E/G ratio of 2.17 and a beta of 0.13. Regeneron Pharmaceuticals has a 52-week low of $688.52 and a 52-week high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The business had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Equities research analysts predict that Regeneron Pharmaceuticals will post 37.23 earnings per share for the current year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.